<div id="readability-page-1"><div>By Billy Gray Novartis said it expected a key profitability metric to decline this year in large part due to increased competition in the U.S. from generic drug competitors. The Swiss pharma major said Wednesday that it expects its core operating profit--one of its preferred metrics, which strips out exceptional items--for 2026 to decline by a low single digit. It expects low single-digit sales growth this year. Novartis said in the performance update that in 2026, it would face the largest drug-patent expiry headwind in its history. Three blockbuster treatments--Entresto, Promacta and Tasigna--lost U.S. patent exclusivity toward the middle of last year, which the group said was the primary catalyst of its guidance toward a short-term profitability fall. Increased competition from generic competitors would generate a roughly $4 billion negative impact in 2026, Harry Kirsch, Novartis's chief financial officer, said in a call with reporters. Fourth-quarter sales for the heart-failure treatment Entresto fell 45% on year at constant currency, to $1.25 billion, while Promacta sales for the period plunged 63% at constant exchange rates, to $226 million. Net sales in the fourth quarter fell 1% at constant currency compared with the prior-year period, to $13.34 billion, the company said. Still, Novartis reiterated that it expects sales to grow through 2030 at a compound annual rate of 5% to 6%. J.P. Morgan analysts said that would lead to a 9% consensus-estimate beat for 2030 sales that would require a number of successful treatment candidates in the pipeline. Changes to U.S. drug pricing to most-favored-nations levels didn't have a material effect on 2026 guidance, Chief Executive Vas Narasimhan said. The company said core operating profit for the year grew to $21.89 billion from $19.49 billion for the year prior, on sales that rose to $54.53 billion from $50.32 billion. Analysts polled by Visible Alpha had forecast $21.85 billion in core operating profit and $54.82 billion in sales. Write to Billy Gray at william.gray@wsj.com (END) Dow Jones Newswires02-04-26 0638ET</div></div>

诺华制药预测，由于美国仿制药竞争加剧，2026 年核心营业利润将出现下降，预计降幅为低个位数。该公司面临重大专利到期，尤其是像 Entresto 和 Promacta 这样的畅销药物，已经出现了显著的销售下降。尽管如此，诺华预计到 2030 年年均销售增长将达到 5-6%。第四季度销售略微下降至 133.4 亿美元，但核心营业利润上升至 218.9 亿美元，略高于分析师预期

Novartis Forecasts Profitability Hit From Generic Drug Competition in U.S. -- Update

marketscreener

诺华制药

标普生物技术 3 倍做空 - Direxion

鹏华上证科创板生物医药ETF

美国制药 ETF - iShares

广发中证香港创新药(QDII-ETF)

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

平安中证医疗创新ETF

创新药

医药突破 ETF - ALPS

招商中证生物科技主题ETF

医疗业 ETF - SPDR

易方达恒生港股通创新药ETF

医疗业 ETF - Vanguard

易方达中证生物科技主题ETF

国泰中证生物医药ETF

华夏中证生物科技主题ETF

Invesco Nasdaq Biotechnology ETF

天弘国证生物医药ETF

博时恒生港股通创新药精选ETF

易方达沪深300医药ETF

纳斯达克生物科技指数 ETF - iShares Nasdaq

南方恒生生物科技ETF(QDII)

标普生物技术 ETF - SPDR

方正富邦中证医药及医疗器械创新ETF

香港医药

博时恒生医疗保健(QDII-ETF)

生物科技ETF基金

华夏上证科创板生物医药ETF

动态生物技术与基因组 ETF - Invesco

科创医药ETF工银

富国恒生港股通创新药及医疗保健ETF

基因改革 ETF - ARK

华宝恒生港股通创新药精选ETF

诺发集团

纽交所高增长板生物技术指数 ETF - First Trust

华夏医药ETF

标普全球医疗股指数 ETF - iShares

华安恒生生物科技ETF

诺华制药预测美国市场的仿制药竞争将对其盈利能力造成冲击 -- 更新